| BE0324-5MG
| InVivoMAb anti-human/mouse denatured collagen type-I (RGD motif)
| 5 mg
| BioXCell
| Western blot, Immunofluorescence, in vivo adminis
|
| Mouse
| human/mous
| Consultar
|
| BE0319-1MG
| InVivoMAb anti-mouse FasL (CD178)
| 1 mg
| BioXCell
| in vivo FasL blockade, in vitro FasL blockade, Fun
|
| Armenian Hamster
| Mouse
| Consultar
|
| BE0324-1MG
| InVivoMAb anti-human/mouse denatured collagen type-I (RGD motif)
| 1 mg
| BioXCell
| Western blot, Immunofluorescence, in vivo adminis
|
| Mouse
| human/mous
| Consultar
|
| BE0334-100MG
| InVivoMAb anti-mouse NKG2D (CD314)
| 100 mg
| BioXCell
| in vivo NKG2D blockade, in vitro NKG2D blockade, F
|
| Rat
| Mouse
| Consultar
|
| BP0017-1-100MG
| InVivoPlus anti-mouse CD154 (CD40L)
| 100 mg
| BioXCell
| in vivo blocking of CD40/CD40L signaling, in vitro
|
| Armenian hamster
| Mouse
| Consultar
|
| BE0311-5MG
| InVivoMAb anti-mouse CD317 (BST2, PDCA-1)
| 5 mg
| BioXCell
| in vivo pDC depletion, Immunofluorescence, Flow cy
|
| Rat
| Mouse
| Consultar
|
| BP0050-50MG
| InVivoPlus anti-mouse IL-10R (CD210)
| 50 mg
| BioXCell
| in vivo blocking of IL-10/IL-10R signaling, in vit
|
| Rat
| Mouse
| Consultar
|
| BE0341-25MG
| InVivoMAb anti-human EphA2
| 25 mg
| BioXCell
| Immunohistochemistry (paraffin), Immunoprecipitati
|
| Mouse
| Human
| Consultar
|
| BE0326-100MG
| InVivoMAb anti-mouse IL-27 p28
| 100 mg
| BioXCell
| in vivo IL-27 p28 neutralization, in vitro IL-27 p
|
| Mouse
| Mouse
| Consultar
|
| BE0344-100MG
| InVivoMAb anti-mouse TIM-4
| 100 mg
| BioXCell
| Flow cytometry
|
| Rat
| Mouse
| Consultar
|
| BE0309-1MG
| InVivoMAb anti-mouse CXCL9 (MIG)
| 1 mg
| BioXCell
| Immunofluorescence
|
| Armenian hamster
| Mouse
| Consultar
|
| BE0345-5MG
| InVivoMAb anti-mouse/rat/bovine VLDL-R
| 5 mg
| BioXCell
| Western blot
|
| Mouse
| mouse/rat/bovin
| Consultar
|
| BP0099-5MG
| InVivoPlus recombinant CTLA-4-Ig (hum./hum.)
| 5 mg
| BioXCell
|
|
| n/a
| n/
| Consultar
|
| BE0312-1MG
| InVivoMAb anti-mouse IFN?
| 1 mg
| BioXCell
| in vivo IFN? neutralization, in vitro IFN? neutral
|
| Armenian hamster
| Mouse
| Consultar
|
| BE0327-25MG
| InVivoMAb anti-human IL-9
| 25 mg
| BioXCell
| Flow cytometry, ELISA
|
| Mouse
| Human
| Consultar
|
| BP0031-25MG
| InVivoPlus anti-mouse OX40 (CD134)
| 25 mg
| BioXCell
| in vivo OX40 activation, in vitro OX40 activation
|
| Rat
| Mouse
| Consultar
|
| BE0330-1MG
| InVivoMAb anti-mouse CD69
| 1 mg
| BioXCell
| in vivo down-regulation of CD69 expression, Functi
|
| Mouse
| Mouse
| Consultar
|
| BP0088-50MG
| InVivoPlus rat IgG1 isotype control (anti-HRP)
| 50 mg
| BioXCell
|
|
| Rat
| n/
| Consultar
|
| BE0318-25MG
| InVivoMAb anti-human Ganglioside GD2
| 25 mg
| BioXCell
| in vitro induction of apoptosis in GD2+ cells, in
|
| Mouse
| Human
| Consultar
|
| BE0316-50MG
| InVivoMAb anti-mouse CCR3 (CD193)
| 50 mg
| BioXCell
| in vivo eosinophil depletion
|
| Rat
| Mouse
| Consultar
|
| BE0304-100MG
| InVivoMAb anti-mouse BTLA (CD272)
| 100 mg
| BioXCell
| in vivo BTLA+ B cell and CD4 T cell depletion, Flo
|
| Mouse
| Mouse
| Consultar
|
| BP0066-50MG
| InVivoPlus anti-mouse Thy1.2 (CD90.2)
| 50 mg
| BioXCell
| in vivo ILC depletion, in vivo T cell depletion
|
| Rat
| Mouse
| Consultar
|
| BE0346-5MG
| InVivoMAb anti-mouse CD326 (EpCAM)
| 5 mg
| BioXCell
| Immunohistochemistry (frozen), Immunofluorescence,
|
| Rat
| Mouse
| Consultar
|
| BE0338-5MG
| InVivoMAb anti-human CD220 (Insulin Receptor)
| 5 mg
| BioXCell
| Western blot
|
| Mouse
| Human
| Consultar
|
| BE0319-5MG
| InVivoMAb anti-mouse FasL (CD178)
| 5 mg
| BioXCell
| in vivo FasL blockade, in vitro FasL blockade, Fun
|
| Armenian Hamster
| Mouse
| Consultar
|
| BE0326-25MG
| InVivoMAb anti-mouse IL-27 p28
| 25 mg
| BioXCell
| in vivo IL-27 p28 neutralization, in vitro IL-27 p
|
| Mouse
| Mouse
| Consultar
|
| BP0045-100MG
| InVivoPlus anti-mouse IL-4
| 100 mg
| BioXCell
| in vitro IL-4 neutralization, in vivo IL-4 neutral
|
| Rat
| Mouse
| Consultar
|
| BE0331-1MG
| InVivoMAb anti-rat/mouse CD71 (TfR1)
| 1 mg
| BioXCell
| Targeted drug delivery to the brain, Immunohistoch
|
| Mouse
| rat/mous
| Consultar
|
| BP0090-50MG
| InVivoPlus rat IgG2b I sotype control
| 50 mg
| BioXCell
|
|
| Rat
| n/
| Consultar
|
| BP0057-100MG
| InVivoPlus anti-mouse/human/rat/monkey/hamster/canine/bovine TGF-?
| 100 mg
| BioXCell
| in vivo TGF? neutralization, in vitro TGF? neutral
|
| Mouse
| mouse/human/rat/monkey/hamster/canine/bovin
| Consultar
|
| BE0311-25MG
| InVivoMAb anti-mouse CD317 (BST2, PDCA-1)
| 25 mg
| BioXCell
| in vivo pDC depletion, Immunofluorescence, Flow cy
|
| Rat
| Mouse
| Consultar
|
| BE0322-50MG
| InVivoMAb anti-mouse CD172a (SIRP?)
| 50 mg
| BioXCell
| in vivo SIRP? blocking, in vitro SIRP? blocking, W
|
| Rat
| Mouse
| Consultar
|
| BE0309-50MG
| InVivoMAb anti-mouse CXCL9 (MIG)
| 50 mg
| BioXCell
| Immunofluorescence
|
| Armenian hamster
| Mouse
| Consultar
|
| BE0322-100MG
| InVivoMAb anti-mouse CD172a (SIRP?)
| 100 mg
| BioXCell
| in vivo SIRP? blocking, in vitro SIRP? blocking, W
|
| Rat
| Mouse
| Consultar
|
| BP0083-5MG
| InVivoPlus mouse IgG1 isotype control
| 5 mg
| BioXCell
|
|
| Mouse
| n/
| Consultar
|
| BE0314-100MG
| InVivoMAb anti-mouse TIM-1 (CD365)
| 100 mg
| BioXCell
| in vivo TIM-1 blockade, in vitro TIM-1 blockade
|
| Rat
| Mouse
| Consultar
|
| BE0300-25MG
| InVivoMAb anti-mouse CD45.2
| 25 mg
| BioXCell
| Flow cytometry, Immunohistochemistry (frozen), in
|
| Mouse
| Mouse
| Consultar
|
| BE0345-25MG
| InVivoMAb anti-mouse/rat/bovine VLDL-R
| 25 mg
| BioXCell
| Western blot
|
| Mouse
| mouse/rat/bovin
| Consultar
|
| BE0335-1MG
| InVivoMAb anti-human MAGE-C2 (CT10)
| 1 mg
| BioXCell
| Immunohistochemistry (paraffin), Immunofluorescenc
|
| Mouse
| Human
| Consultar
|
| BE0305-25MG
| InVivoMAb anti-mouse CLEC9A (CD370)
| 25 mg
| BioXCell
| in vivo Ag targeting to CLEC9A+ DCs, Western blot,
|
| Rat
| Mouse
| Consultar
|
| BE0312-25MG
| InVivoMAb anti-mouse IFN?
| 25 mg
| BioXCell
| in vivo IFN? neutralization, in vitro IFN? neutral
|
| Armenian hamster
| Mouse
| Consultar
|
| BP0088-5MG
| InVivoPlus rat IgG1 isotype control (anti-HRP)
| 5 mg
| BioXCell
|
|
| Rat
| n/
| Consultar
|
| BE0298-50MG
| InVivoMAb anti-mouse CD122 (IL-2R?)
| 50 mg
| BioXCell
| in vivo NK cell depletion, in vitro IL-2R blockade
|
| Rat
| Mouse
| Consultar
|
| BP0101-25MG
| InVivoPlus anti-mouse PD-L1 (B7-H1)
| 25 mg
| BioXCell
| in vivo PD-L1 blockade, Immunofluorescence, Immuno
|
| Rat
| Mouse
| Consultar
|
| BE0325-1MG
| InVivoMAb anti-West Nile/dengue virus E protein
| 1 mg
| BioXCell
| Neutralization of WNV, Neutralization of DENV1,2,3
|
| Mouse
| West Nile/dengue viru
| Consultar
|
| BP0099-50MG
| InVivoPlus recombinant CTLA-4-Ig (hum./hum.)
| 50 mg
| BioXCell
|
|
| n/a
| n/
| Consultar
|
| BP0090-5MG
| InVivoPlus rat IgG2b I sotype control
| 5 mg
| BioXCell
|
|
| Rat
| n/
| Consultar
|
| BE0330-100MG
| InVivoMAb anti-mouse CD69
| 100 mg
| BioXCell
| in vivo down-regulation of CD69 expression, Functi
|
| Mouse
| Mouse
| Consultar
|
| BE0298-1MG
| InVivoMAb anti-mouse CD122 (IL-2R?)
| 1 mg
| BioXCell
| in vivo NK cell depletion, in vitro IL-2R blockade
|
| Rat
| Mouse
| Consultar
|
| BE0329-5MG
| InVivoMAb anti-mouse CD71 (TfR1)
| 5 mg
| BioXCell
| in vivo depletion of CD71+ cells, Immunofluorescen
|
| Rat
| Mouse
| Consultar
|